Kyverna Therapeutics (KYTX) investor relations material

Executive summary

• Completed the rolling miv-cel BLA submission for SPS in Q4 2026, requesting FDA priority review under RMAT; a potential 2027 U.S. launch is subject to approval.

• Commercial preparations are progressing; gMG Phase 3 enrollment is expected to finish by mid-2027, and a progressive MS development-strategy update is expected by early 2027.

• KYV-102 manufacturing work was deprioritized to focus resources on late-stage neurologic indications.

Financial highlights

• Q3 R&D expense was $27.023M versus $30.457M YoY; G&A was $15.876M versus $8.270M, and total operating expenses were $42.899M versus $38.727M.

• Q3 net loss was $41.941M versus $36.787M YoY; nine-month net loss was $119.988M versus $123.503M.

• Nine-month operating expenses were $123.822M versus $130.545M YoY, including R&D of $81.884M and G&A of $41.938M.

Outlook and guidance

• Cash, cash equivalents, marketable securities and available Oxford Finance loan capacity are expected to fund operations into 2028; the financial statements indicate a runway of at least 12 months.

• A potential 2027 SPS launch is subject to FDA approval; preparation includes treatment-center engagement, patient support and reimbursement infrastructure.

• KYSA-6 Phase 3 gMG enrollment is expected to complete by mid-2027; a progressive MS development-strategy update is expected by early 2027.

• Expenses are expected to rise with clinical development, manufacturing, regulatory work and commercial readiness; additional capital may be needed beyond the current runway.